Travere Therapeutics (TVTX) drew fresh attention after the USPTO issued a Notice of Allowance for a FILSPARI patent in IgA nephropathy, which is expected to extend certain U.S. protections into October 2037.

The patent news lands after a strong run in the stock, with a 30-day share price return of 16.8% and a 90-day share price return of 60.32%. The 1-year total shareholder return sits at 210.53%, which suggests momentum has been building into the latest update.

If this kind of move in a rare-disease biotech has caught your attention, it could be a good moment to scan other potential healthcare opportunities through 35 healthcare AI stocks

With Travere trading at $47.76, sitting about 13% below the average analyst price target of $54.14 and with an intrinsic value estimate implying a larger discount, investors now face a key question: is there genuine upside left, or is the market already pricing in future growth?

Most Popular Narrative: 10.8% Undervalued

Travere Therapeutics' most followed narrative pegs fair value at $53.57, above the last close at $47.76, which frames the recent patent news against a higher long term earnings and margin story.

Travere's strengthening financial position, driven by rapid product sales growth, increased international out-licensing revenues, significant reductions in net losses, and prudent R&D and SG&A management, sets a foundation for positive net earnings, while securing resources for continued pipeline development and future commercial launches. (Earnings, cash flow, R&D investment)

Want to see what is behind that confidence in future profits and cash flows? The narrative leans heavily on rising revenue, expanding margins and a higher future earnings multiple.

Result: Fair Value of $53.57 (UNDERVALUED)

However, the story can change quickly if FILSPARI faces tougher competition than analysts expect, or if ongoing R&D and commercial spending keeps net margins under pressure.

Another Way To Look At The Valuation

The popular narrative leans on long term earnings forecasts, but the current P/S ratio of 8.3x paints a different picture. It sits cheaper than the US Biotechs average of 10.6x, yet above both close peers at 7.1x and a fair ratio of 6.4x. This points to meaningful valuation risk if expectations cool.

To see how this revenue based view compares with detailed cash flow assumptions and future scenarios, take a closer look at our valuation breakdown through See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Seeing both the optimism and the concerns laid out, do you feel the balance tips one way yet, or is it still undecided? Act while the information is fresh and weigh the upside against the downside by checking the 3 key rewards and 2 important warning signs

Looking for more investment ideas?

If Travere has sharpened your focus, do not stop here. Broaden your watchlist with fresh ideas that match your style before the next move passes you by.

• Target potential mispricing by scanning 46 high quality undervalued stocks that combine quality fundamentals with room for sentiment to catch up.
• Strengthen your income stream by reviewing 10 dividend fortresses designed for investors who want yield without ignoring business quality.
• Prioritise resilience by checking 64 resilient stocks with low risk scores where balance sheets and risk scores help you sleep better at night.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.